Trial Profile

Assessment of cetrorelix pamoate intermittent IM administration on ECG, PK and PD parameters in healthy male volunteers - a Thorough QT assesment to address the ICH-E14 guidelines

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetrorelix (Primary) ; Moxifloxacin
Indications Bacterial infections; Benign prostatic hyperplasia
Focus Adverse reactions
Sponsors AEterna Zentaris Inc; Celerion

Most Recent Events

05 Mar 2011 Pharmacokinetic and pharmacodynamic results presented at the 112th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
08 Oct 2009 New trial record.
30 Sep 2009 Primary endpoint 'no increase in heart rate-corrected QT interval' has been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com